Stay updated on SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record is now available, including its study design, eligibility criteria, treatment arms, outcome measures, recruitment status, and administrative details, instead of displaying an access-denied error.
    Difference
    75%
    Check dated 2026-11-11T00:58:47.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-11-03T23:15:40.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide notice about NIH’s terminology transition was added, and the site revision changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:49:48.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T22:45:47.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error screen in place of the study details, indicating an access issue. The added 403 header and text contrast with the removal of typical study metadata, showing that the page content is not currently retrievable rather than a content update.
    Difference
    22%
    Check dated 2026-09-22T23:06:28.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now displays a Study status section and the revision label was updated from v3.6.6 to v3.7.0, replacing the previous Status label.
    Difference
    0.1%
    Check dated 2026-09-15T21:01:37.000Z thumbnail image

Stay in the know with updates to SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial page.